Translate Bio (NASDAQ:TBIO) Given a $17.00 Price Target by Citigroup Analysts
Translate Bio (NASDAQ:TBIO) has been given a $17.00 price objective by equities research analysts at Citigroup in a research report issued to clients and investors on Tuesday, TipRanks reports. The firm presently has a “buy” rating on the stock. Citigroup‘s target price indicates a potential upside of 65.53% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Translate Bio from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Jefferies Financial Group initiated coverage on shares of Translate Bio in a research note on Monday, July 22nd. They set a “buy” rating and a $20.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Translate Bio in a report on Thursday, August 1st. Finally, Roth Capital assumed coverage on shares of Translate Bio in a research report on Tuesday, June 18th. They issued a “buy” rating and a $25.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $20.60.
TBIO traded up $0.46 during trading on Tuesday, reaching $10.27. The company had a trading volume of 254,297 shares, compared to its average volume of 219,033. The stock has a market cap of $523.87 million, a P/E ratio of -2.82 and a beta of 0.90. The business has a 50 day simple moving average of $8.71 and a 200-day simple moving average of $9.82. Translate Bio has a 52 week low of $4.81 and a 52 week high of $14.34. The company has a quick ratio of 7.67, a current ratio of 7.67 and a debt-to-equity ratio of 1.15.
Several hedge funds and other institutional investors have recently modified their holdings of TBIO. Baupost Group LLC MA lifted its stake in shares of Translate Bio by 36.2% during the 2nd quarter. Baupost Group LLC MA now owns 8,844,239 shares of the company’s stock worth $109,372,000 after acquiring an additional 2,352,941 shares during the last quarter. BlackRock Inc. increased its stake in Translate Bio by 28.0% in the second quarter. BlackRock Inc. now owns 2,515,392 shares of the company’s stock worth $31,769,000 after purchasing an additional 549,817 shares during the period. Vanguard Group Inc. increased its stake in Translate Bio by 80.6% in the second quarter. Vanguard Group Inc. now owns 1,524,907 shares of the company’s stock worth $19,259,000 after purchasing an additional 680,330 shares during the period. Artal Group S.A. lifted its position in shares of Translate Bio by 25.0% during the second quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock worth $9,473,000 after purchasing an additional 150,000 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Translate Bio by 7.5% during the second quarter. Northern Trust Corp now owns 310,246 shares of the company’s stock worth $3,919,000 after purchasing an additional 21,593 shares during the last quarter. Hedge funds and other institutional investors own 72.68% of the company’s stock.
Translate Bio Company Profile
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Further Reading: What is a Derivative?
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.